India’s drug regulator has approved Novo Nordisk’s obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The approval covers the 2.4 mg semaglutide injection and marks another significant milestone for the blockbuster drug, which is already approved in India for chronic weight Continue Reading
